{
    "Trade/Device Name(s)": [
        "FLC Kappa",
        "FLC Lambda"
    ],
    "Submitter Information": "Sebia, Inc.",
    "510(k) Number": "K231601",
    "Predicate Device Reference 510(k) Number(s)": [
        "K031016"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DFH",
        "DEH"
    ],
    "Summary Letter Date": "February 23, 2024",
    "Summary Letter Received Date": "January 12, 2024",
    "Submission Date": "February 16, 2024",
    "Regulation Number(s)": [
        "21CFR866.5550",
        "21CFR862.1660"
    ],
    "Regulation Name(s)": [
        "Immunoglobulin (Light Chain Specific) Immunological Test System",
        "Quality Control Material (Assayed and Unassayed)"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Kappa free light chain",
        "Lambda free light chain"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Densitometer for microplate reading by absorbance spectrophotometry at 450 nm"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme-Linked Immunosorbent Assay (ELISA)"
    ],
    "Methodologies": [
        "Sandwich ELISA"
    ],
    "Submission Type(s)": [
        "Kit",
        "Control",
        "Calibrator",
        "Microplate"
    ],
    "Document Summary": "FDA 510(k) summary for Sebia FLC Kappa and FLC Lambda ELISA kits for quantification of free light chains in human serum aiding diagnosis and monitoring of multiple myeloma and AL amyloidosis",
    "Indications for Use Summary": "Intended for quantification of Kappa and Lambda free light chains in human serum from adults using ELISA; aids in diagnosis and monitoring of multiple myeloma and AL amyloidosis, used in conjunction with other laboratory and clinical findings",
    "fda_folder": "Immunology"
}